143 related articles for article (PubMed ID: 38331327)
1. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
[TBL] [Abstract][Full Text] [Related]
2. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
[TBL] [Abstract][Full Text] [Related]
3. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
4. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma.
Yoshida Y; Yoshio S; Yamazoe T; Mori T; Tsustui Y; Kawai H; Yoshikawa S; Fukuhara T; Okamoto T; Ono Y; Takahashi Y; Hashida R; Kawaguchi T; Taketomi A; Kanto T
Cells; 2021 Jun; 10(6):. PubMed ID: 34198593
[TBL] [Abstract][Full Text] [Related]
6. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma.
Zhang P; Lu X; Tao K; Shi L; Li W; Wang G; Wu K
J Surg Res; 2015 Mar; 194(1):107-13. PubMed ID: 25450598
[TBL] [Abstract][Full Text] [Related]
7. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
8. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
9. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
11. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
12. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells.
Adeniji OS; Kuri-Cervantes L; Yu C; Xu Z; Ho M; Chew GM; Shikuma C; Tomescu C; George AF; Roan NR; Ndhlovu LC; Liu Q; Muthumani K; Weiner DB; Betts MR; Xiao H; Abdel-Mohsen M
PLoS Pathog; 2021 Nov; 17(11):e1010034. PubMed ID: 34762717
[TBL] [Abstract][Full Text] [Related]
13. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.
Chew V; Tow C; Huang C; Bard-Chapeau E; Copeland NG; Jenkins NA; Weber A; Lim KH; Toh HC; Heikenwalder M; Ng IO; Nardin A; Abastado JP
J Natl Cancer Inst; 2012 Dec; 104(23):1796-807. PubMed ID: 23197495
[TBL] [Abstract][Full Text] [Related]
15. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
17. Blocking siglec-10
Xiao N; Zhu X; Li K; Chen Y; Liu X; Xu B; Lei M; Xu J; Sun HC
Exp Hematol Oncol; 2021 Jun; 10(1):36. PubMed ID: 34112250
[TBL] [Abstract][Full Text] [Related]
18. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
19. Increased Frequency of Dysfunctional Siglec-7
Sakamoto Y; Yoshio S; Doi H; Mori T; Matsuda M; Kawai H; Shimagaki T; Yoshikawa S; Aoki Y; Osawa Y; Yoshida Y; Arai T; Itokawa N; Atsukawa M; Ito T; Honda T; Mise Y; Ono Y; Takahashi Y; Saiura A; Taketomi A; Kanto T
Front Immunol; 2021; 12():603133. PubMed ID: 33692781
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
